Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGDR2 | Q9Y5Y4 | 3/20 | 0.54 |
| ▸ | PTGDR | Q13258 | 2/20 | 0.54 |
| ▸ | POLB | P06746 | 3/20 | 0.44 |
| ▸ | PABPC1 | P11940 | 1/20 | 0.44 |
| ▸ | APOBEC3A | P31941 | 1/20 | 0.44 |
| ▸ | APOBEC3G | Q9HC16 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 9/20 | 0.44 |
| ▸ | HPGD | P15428 | 6/20 | 0.44 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.41 |
| ▸ | MAPT | P10636 | 2/20 | 0.41 |
| ▸ | MEN1 | O00255 | 2/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
| ▸ | LMNA | P02545 | 2/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | CASP6 | P55212 | 1/20 | 0.41 |
| ▸ | ATM | Q13315 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4886176 | 0.85 | PTGDR2 (0.73) | PTGDR2PTGDRPOLBALDH1A1HPGD | |
| SCHEMBL17847413 | 0.79 | PTGDR (0.44) | PTGDR2PTGDRPOLBALDH1A1HPGD | |
| SCHEMBL16559854 | 0.78 | ALDH1A1 (0.55) | PTGDR2POLBPABPC1APOBEC3AAPOBEC3G | |
| SCHEMBL4517104 | 0.76 | MEN1 (0.57) | PTGDR2POLBPABPC1APOBEC3AAPOBEC3G | |
| SCHEMBL27642138 | 0.75 | ALDH1A1 (0.52) | PTGDR2POLBPABPC1APOBEC3AAPOBEC3G | |
| SCHEMBL5106323 | 0.74 | ALDH1A1 (0.65) | PTGDR2POLBPABPC1APOBEC3AAPOBEC3G | |
| SCHEMBL27623122 | 0.74 | POLB (0.51) | PTGDR2POLBPABPC1APOBEC3AAPOBEC3G | |
| SCHEMBL4303747 | 0.74 | ALDH1A1 (0.65) | POLBPABPC1APOBEC3AAPOBEC3GALDH1A1 | |
| SCHEMBL5827697 | 0.73 | RARA (0.50) | PTGDR2PTGDRALDH1A1KDM4EMEN1 | |
| SCHEMBL1997089 | 0.73 | PTGDR2 (0.69) | PTGDR2POLBPABPC1APOBEC3AAPOBEC3G |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080269335-A1 | 2-(4-Chloro-2-cyclohexylphenoxy)propionic acid; (4-Bromo-2-cyclohexylphenoxy)propionic acid ethyl ester; ethyl-2-bromopropionate is reacted with 4-chloro-2-cyclohexylphenol in presence of cesium carbonate and N,N-dimethylfomamide; antiallergenic and antiinflammatory agent | NOVARTIS AG (CH) | 2008-10-30 | — | — | US | disclosed |
| EP-1756032-A1 | CRTH2 RECEPTOR ANTAGONISTS | Novartis AG (CH) | 2007-02-28 | — | — | EP | disclosed |
| WO-2005105727-A1 | CRTH2 RECEPTOR ANTAGONISTS | NOVARTIS AG (CH) | 2005-11-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080269335-A1 | 2-(4-Chloro-2-cyclohexylphenoxy)propionic acid; (4-Bromo-2-cyclohexylphenoxy)propionic acid ethyl ester; ethyl-2-bromopropionate is reacted with 4-chloro-2-cyclohexylphenol in presence of cesium carbonate and N,N-dimethylfomamide; antiallergenic and antiinflammatory agent | EPX, NR3C2, FPR2 | PTGDR2 245/4885PTGDR 151/4885POLB 2275/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.